NeuroSense Therapeutics Ltd.
(Note: This is a unit offering of 1.85 million units. Each unit consists of one ordinary share and one warrant to purchase one ordinary share. After the IPO, the stock is expected to trade on the NASDAQ under the symbol “NRSN” and the warrants are expected to trade on the NASDAQ under the symbol “NRSNW”.) (Incorporated in Israel)
Our goal is to develop therapeutics to defeat neurodegenerative diseases. We are a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. We believe that these diseases, which include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. The burden of these diseases on both patients and society is substantial. For example, the average annual cost of ALS alone is $180,000 per patient, and its estimated annual burden on the U.S. healthcare system is greater than $1 billion. Due to the complexity of neurodegenerative diseases, our strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
Our lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. Ciprofloxacin was approved to treat or prevent a variety of bacterial infections and celecoxib was approved as a prescription nonsteroidal anti-inflammatory drug used to treat pain. PrimeC is designed to treat ALS by regulating microRNA, or miRNA, synthesis, influencing iron accumulation and reducing neuroinflammation, all of which are hallmarks of ALS pathologies. The U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA, have both granted PrimeC an orphan drug designation for the treatment of ALS. We believe PrimeC’s multifactorial mechanism of action has the potential to significantly prolong lifespan and improve ALS patients’ quality of life, thereby reducing the burden of this debilitating disease on both patients and healthcare systems.
In addition to PrimeC, we recently initiated research and development efforts in Alzheimer’s disease and Parkinson’s disease, with a similar strategy of combined products.
(Note: NeuroSense Therapeutics priced its IPO – a unit offering – on Dec. 8, 2021, by slightly increasing the number of units to 2.0 million, up from 1.85 million in the prospectus, and pricing each unit at $6 – the low end of its $6-to-$7 price range – to raise $12 million.)
|Address||Medinat ha-Yehudim Street 85 Herzliya 4676670 Israel|
|View Prospectus:||NeuroSense Therapeutics Ltd.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-5.26 mil (last 12 months)|
|Price range||$6.00 - $6.00|
|Est. $ Volume||$12.0 mil|
|Manager / Joint Managers||Maxim Group|
|Expected To Trade:||12/9/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|